Oslo, Norway, 16 May 2018 – Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that members of its senior management will present at the following life sciences and investor conferences:
Date: 17 May 2018
Poster presentation:
The Combinatory Treatment of the Oncolytic Adenovirus ONCOS-102 with Anti PD-1 (Keytruda®) Show Synergistic Anti-Tumor Effect in Humanized A2058 Melanoma huNOG Mouse Model
Venue: 21st Annual Meeting of the American Society of Gene & Cell Therapy, Chicago, USA
Presentation time: 5:15 PM – 7:15 PM CDT
Presenter: Anne-Sophie Møller (Head of Clinical Science) and Lukasz Kuryk (Director, Clinical Science)
Date: 23 May 2018
Venue: ABGSC Cancer Seminar, Stockholm, Sweden
Presentation time: 09:00 CET
Presenter: Magnus Jäderberg (CMO)
Date: 28 May 2018
Venue: Redeye Pre-ASCO Seminar, Stockholm, Sweden
Presentation time: 11:05 CET
Presenter: Erik Digman Wiklund (CFO)
The presentations will be available to download at www.circio.com following these events.
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
Simon Conway/Stephanie Cuthbert – FTI Consulting (International)
Phone: +44 20 3727 1000
Email: Targovax@fticonsulting.com
About Targovax
Arming the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage company focused on developing and commercializing novel immuno-oncology therapies to target, primarily, treatment-resistant solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine.
The Company’s development pipeline is based on two novel proprietary platforms:
The first platform, ONCOS, uses oncolytic viruses as potential multi-target, neo-antigen therapeutic cancer vaccines. ONCOS uses an adenovirus that has been engineered to be an immune activator that selectively targets cancer cells. In phase I trials it has demonstrated immune activation at lesional level which was associated with clinical benefit. In an ongoing phase I trial in advanced melanoma we expect important proof of concept data for checkpoint inhibitor refractory patients.
The second platform, TG, are neo-antigen cancer vaccines designed to specifically treat tumors that express mutated forms of RAS. Mutations to the RAS protein are common in many cancers and are known to drive aggressive disease progression and treatment resistance. There is a high unmet medical need for therapies that are effective against tumors that express these mutations. The TG platform’s therapeutic potential stems from its ability to enable the patient’s immune system to identify and destroy tumors bearing any RAS mutations. In early 2017, key proof of concept data for the TG platform from a clinical trial of TG01 in resected pancreatic cancer patients showed encouraging overall survival and will give guidance for the future clinical development of this platform.
Targovax’s development pipeline has three novel therapeutic candidates in clinical development covering six indications.
Both platforms are protected by an extensive portfolio of IP and know-how and have the potential to yield multiple product candidates in a cost-effective manner. Additionally, Targovax has other products in early stages of development.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.